F-star Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022024526 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.57M $71.05M
YoY Change -49.94% 255.59%
Cash & Equivalents $35.60M $71.05M
Short-Term Investments
Other Short-Term Assets $5.896M $3.173M
YoY Change 85.82% 22.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables $436.0K
Total Short-Term Assets $49.61M $76.16M
YoY Change -34.86% 237.29%
LONG-TERM ASSETS
Property, Plant & Equipment $879.0K $1.011M
YoY Change -13.06% -47.51%
Goodwill $14.12M $14.89M
YoY Change -5.16%
Intangibles $16.20M $18.79M
YoY Change -13.79%
Long-Term Investments
YoY Change
Other Assets $412.0K $450.0K
YoY Change -8.44% 92.31%
Total Long-Term Assets $34.11M $38.64M
YoY Change -11.72% 728.41%
TOTAL ASSETS
Total Short-Term Assets $49.61M $76.16M
Total Long-Term Assets $34.11M $38.64M
Total Assets $83.72M $114.8M
YoY Change -27.07% 321.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.501M $1.569M
YoY Change 59.4% -49.95%
Accrued Expenses $7.747M $5.642M
YoY Change 37.31% 103.17%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $1.315M $0.00
YoY Change
Long-Term Debt Due $1.315M
YoY Change
Total Short-Term Liabilities $14.68M $8.835M
YoY Change 66.1% 41.36%
LONG-TERM LIABILITIES
Long-Term Debt $8.525M $9.535M
YoY Change -10.59%
Other Long-Term Liabilities $3.572M $5.774M
YoY Change -38.14% 114.65%
Total Long-Term Liabilities $8.525M $15.31M
YoY Change -44.31% 469.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.68M $8.835M
Total Long-Term Liabilities $8.525M $15.31M
Total Liabilities $26.78M $24.72M
YoY Change 8.33% 176.82%
SHAREHOLDERS EQUITY
Retained Earnings -$127.9M -$83.20M
YoY Change 53.73% -43.09%
Common Stock $2.000K $2.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.94M $90.08M
YoY Change
Total Liabilities & Shareholders Equity $83.72M $114.8M
YoY Change -27.07% 321.43%

Cashflow Statement

Concept 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001566373
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37718
dei Entity Registrant Name
EntityRegistrantName
F-STAR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2386345
dei Entity Address Address Line1
EntityAddressAddressLine1
Eddeva B920 Babraham Research Campus
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB22 3AT
dei City Area Code
CityAreaCode
44
dei Local Phone Number
LocalPhoneNumber
1223-497400
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per
dei Trading Symbol
TradingSymbol
FSTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21981919
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35568000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78549000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5896000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3879000
CY2022Q3 fstx Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
8145000
CY2021Q4 fstx Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
2311000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
49609000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
84739000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
879000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
887000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2501000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3281000
CY2022Q3 us-gaap Goodwill
Goodwill
14117000
CY2021Q4 us-gaap Goodwill
Goodwill
14898000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16199000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18765000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
412000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
451000
CY2022Q3 us-gaap Assets
Assets
83717000
CY2021Q4 us-gaap Assets
Assets
123021000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2501000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3081000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7747000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6241000
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
1315000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
2286000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1907000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
826000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
906000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14675000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12135000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8525000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9605000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1560000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1694000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2012000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2723000
CY2022Q3 fstx Deferred Taxes Liabilities
DeferredTaxesLiabilities
7000
CY2021Q4 fstx Deferred Taxes Liabilities
DeferredTaxesLiabilities
7000
CY2022Q3 us-gaap Liabilities
Liabilities
26779000
CY2021Q4 us-gaap Liabilities
Liabilities
26164000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21981919
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21981919
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20874590
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20874590
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183310000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
176808000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1565000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1502000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127939000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78451000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
56938000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
96857000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83717000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123021000
CY2022Q3 us-gaap Revenues
Revenues
1125000
CY2021Q3 us-gaap Revenues
Revenues
751000
us-gaap Revenues
Revenues
3676000
us-gaap Revenues
Revenues
3668000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9670000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5113000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26431000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20536000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5161000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5239000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18320000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18169000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
14831000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
10352000
us-gaap Costs And Expenses
CostsAndExpenses
44751000
us-gaap Costs And Expenses
CostsAndExpenses
38705000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13706000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9601000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41075000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35037000
CY2022Q3 us-gaap Interest Expense
InterestExpense
378000
CY2021Q3 us-gaap Interest Expense
InterestExpense
325000
us-gaap Interest Expense
InterestExpense
1020000
us-gaap Interest Expense
InterestExpense
522000
CY2022Q3 fstx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
-60000
CY2021Q3 fstx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
-444000
fstx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
-245000
fstx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
-1027000
CY2022Q3 fstx Other Income Expense
OtherIncomeExpense
4263000
CY2021Q3 fstx Other Income Expense
OtherIncomeExpense
-421000
fstx Other Income Expense
OtherIncomeExpense
-7148000
fstx Other Income Expense
OtherIncomeExpense
752000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4701000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1190000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8413000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
797000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18407000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10791000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49488000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35834000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
190000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18407000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10791000
us-gaap Net Income Loss
NetIncomeLoss
-49488000
us-gaap Net Income Loss
NetIncomeLoss
-36024000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.35
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21856193
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21856193
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20617822
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20617822
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21507219
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21507219
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15300433
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15300433
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18407000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10791000
us-gaap Net Income Loss
NetIncomeLoss
-49488000
us-gaap Net Income Loss
NetIncomeLoss
-36024000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2257000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
117000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3067000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-65000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16150000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10674000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46421000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36089000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
71637000
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
41000
CY2022Q3 fstx Rsu Vesting Net Of Shares Repurchased To Cover Tax Withholding
RsuVestingNetOfSharesRepurchasedToCoverTaxWithholding
-36000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1446000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2257000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18407000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
56938000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
99237000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1515000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
117000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10791000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
90078000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
96857000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
41000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2269000
fstx Rsu Vesting Net Of Shares Repurchased To Cover Tax Withholding
RsuVestingNetOfSharesRepurchasedToCoverTaxWithholding
-124000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4316000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3067000
us-gaap Net Income Loss
NetIncomeLoss
-49488000
CY2022Q3 us-gaap Shares Outstanding
SharesOutstanding
21981919
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
56938000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
42994000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
326000
fstx Issuance Of Common Stock In Connection With Public Offering Net Of Issuance Costs
IssuanceOfCommonStockInConnectionWithPublicOfferingNetOfIssuanceCosts
9115000
fstx Stock Issued During Period Value Initial Public Offering
StockIssuedDuringPeriodValueInitialPublicOffering
68178000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-65000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5554000
us-gaap Net Income Loss
NetIncomeLoss
-36024000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
90078000
us-gaap Profit Loss
ProfitLoss
-49488000
us-gaap Profit Loss
ProfitLoss
-36024000
us-gaap Share Based Compensation
ShareBasedCompensation
4316000
us-gaap Share Based Compensation
ShareBasedCompensation
5554000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7207000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
66000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
38000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9000
us-gaap Depreciation
Depreciation
341000
us-gaap Depreciation
Depreciation
435000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
189000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65000
us-gaap Paid In Kind Interest
PaidInKindInterest
97000
us-gaap Paid In Kind Interest
PaidInKindInterest
42000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
139000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
69000
fstx Fair Value Adjustments
FairValueAdjustments
245000
fstx Fair Value Adjustments
FairValueAdjustments
1027000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2796000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-356000
fstx Increase Decrease In Tax Incentive Receivable
IncreaseDecreaseInTaxIncentiveReceivable
7107000
fstx Increase Decrease In Tax Incentive Receivable
IncreaseDecreaseInTaxIncentiveReceivable
-2083000
fstx Increase Decrease In Operating Rou Asset
IncreaseDecreaseInOperatingRouAsset
643000
fstx Increase Decrease In Operating Rou Asset
IncreaseDecreaseInOperatingRouAsset
749000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-125000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3050000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2336000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3796000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-305000
fstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-654000
fstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-400000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
778000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44695000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34048000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
282000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
658000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
111000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-355000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-643000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2310000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
77295000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9753000
fstx Payment To Tax Authorities In Connection With Shares Directly Withheld From Employees
PaymentToTaxAuthoritiesInConnectionWithSharesDirectlyWithheldFromEmployees
123000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2187000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87048000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42863000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52357000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-118000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78549000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18526000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35568000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71050000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-84000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
36000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Interest Paid Net
InterestPaidNet
782000
us-gaap Interest Paid Net
InterestPaidNet
296000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1468000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
326000
CY2020Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-4
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.0001
CY2022Q2 fstx Offer Price Per Share
OfferPricePerShare
7.12
CY2022Q2 fstx Termination Fee
TerminationFee
7250000
CY2022Q3 fstx Net Assets Current
NetAssetsCurrent
34900000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10200000
CY2022Q3 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
1600000
CY2021Q4 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
1700000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127900000
CY2022Q3 us-gaap Cash
Cash
35600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting years. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of the assets and liabilities acquired in the transaction between Spring Bank and F-star Ltd, the fair value of contingent value rights, the accrual for research and development expenses, revenue recognition, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income and other taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk and of significant suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company is dependent on contract research organizations to provide its clinical trials and third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">supplies </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127900000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35600000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18407000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10791000
us-gaap Net Income Loss
NetIncomeLoss
-49488000
us-gaap Net Income Loss
NetIncomeLoss
-36024000
CY2022Q3 fstx Weighted Average Number Of Shares Outstanding Basic Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfSharesOutstandingBasicWeightedAverageNumberOfDilutedSharesOutstanding
21856193
CY2021Q3 fstx Weighted Average Number Of Shares Outstanding Basic Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfSharesOutstandingBasicWeightedAverageNumberOfDilutedSharesOutstanding
20617822
fstx Weighted Average Number Of Shares Outstanding Basic Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfSharesOutstandingBasicWeightedAverageNumberOfDilutedSharesOutstanding
21507219
fstx Weighted Average Number Of Shares Outstanding Basic Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfSharesOutstandingBasicWeightedAverageNumberOfDilutedSharesOutstanding
15300433
CY2022Q3 fstx Earnings Per Share Basic Earnings Per Share Diluted
EarningsPerShareBasicEarningsPerShareDiluted
-0.84
CY2021Q3 fstx Earnings Per Share Basic Earnings Per Share Diluted
EarningsPerShareBasicEarningsPerShareDiluted
-0.52
fstx Earnings Per Share Basic Earnings Per Share Diluted
EarningsPerShareBasicEarningsPerShareDiluted
-2.30
fstx Earnings Per Share Basic Earnings Per Share Diluted
EarningsPerShareBasicEarningsPerShareDiluted
-2.35
CY2022Q3 us-gaap Goodwill Gross
GoodwillGross
14117000
CY2022Q3 fstx Indefinite Lived Intangible Assets Gross
IndefiniteLivedIntangibleAssetsGross
16044000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4214000
CY2021Q4 us-gaap Goodwill Gross
GoodwillGross
14898000
CY2021Q4 fstx Indefinite Lived Intangible Assets Gross
IndefiniteLivedIntangibleAssetsGross
18961000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4473000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-317000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-130000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
3742000
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
4539000
CY2022Q3 us-gaap Goodwill
Goodwill
14117000
CY2022Q3 fstx Indefinite Lived Intangible Assets
IndefiniteLivedIntangibleAssets
12302000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3897000
CY2021Q4 us-gaap Goodwill
Goodwill
14898000
CY2021Q4 fstx Indefinite Lived Intangible Assets
IndefiniteLivedIntangibleAssets
14422000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4343000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2579000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2543000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1700000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1656000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
879000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
887000
us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
400000
CY2022Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
3846000
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
3601000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
2300000
CY2021 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1900000
CY2022Q3 fstx Accrued Clinical Trail Costs Current
AccruedClinicalTrailCostsCurrent
4270000
CY2021Q4 fstx Accrued Clinical Trail Costs Current
AccruedClinicalTrailCostsCurrent
2834000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1760000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1819000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
949000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1135000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
768000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
453000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7747000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6241000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
300000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
300000
us-gaap Debt Instrument Term
DebtInstrumentTerm
P48M
CY2022Q3 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0625
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0325
us-gaap Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
0.0325
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1175
us-gaap Line Of Credit Facility Frequency Of Payment And Payment Terms
LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
The Company may, at its option upon at least five business days’ written notice to Horizon, prepay all or any portion of the outstanding Term Loan by simultaneously paying to Horizon an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Term Loan so prepaid; plus (ii) an amount equal to (A) if such Term Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Term Loan, three percent of the then outstanding principal balance of such Term Loan, (B) if such Term Loan is prepaid after the Loan Amortization Date applicable to such Term Loan, but on or before the date that is 12 months after such Loan Amortization Date, two percent of the then outstanding principal balance of such Term Loan, or (C) if such Term Loan is prepaid more than 12 months after the Loan Amortization Date applicable to such Term Loan, one percent of the then outstanding principal balance of such Term Loan; plus (iii) the outstanding principal balance of such Term Loan; plus (iv) all other sums, if any, that had become due and payable under the Loan and Security Agreement.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9745
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9718
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
137000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
197000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
23000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
198000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
9840000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
9605000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
100000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
42236
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.47
CY2021Q1 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
10
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
42236
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
121153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021 fstx Increase In Total Number Of Shares Outstanding Percentage
IncreaseInTotalNumberOfSharesOutstandingPercentage
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0284
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0336
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0134
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9563
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9896
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1446000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1515000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4316000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5554000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
751000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3676000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3668000
us-gaap Amount Of Regulatory Assistance Received1
AmountOfRegulatoryAssistanceReceived1
17500000
CY2022Q3 fstx Receivable In Respect Of License Agreement
ReceivableInRespectOfLicenseAgreement
0
CY2021Q3 fstx Receivable In Respect Of License Agreement
ReceivableInRespectOfLicenseAgreement
0
fstx Upfront Fee Received
UpfrontFeeReceived
1000000.0
CY2022Q3 fstx Milestone Payment Receivable
MilestonePaymentReceivable
40000000.0
CY2021Q3 fstx Upfront Fee Received
UpfrontFeeReceived
1000000.0
CY2021Q3 fstx Payment Received Pursuant To License Agreement
PaymentReceivedPursuantToLicenseAgreement
250000
fstx Payment Received Pursuant To License Agreement
PaymentReceivedPursuantToLicenseAgreement
250000
fstx Option Exercise Recognized Revenue
OptionExerciseRecognizedRevenue
1125000
CY2022Q3 fstx Option Exercise Recognized Revenue
OptionExerciseRecognizedRevenue
1125000
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
0
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
us-gaap Operating Lease Cost
OperatingLeaseCost
800000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
206000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
829000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
393000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
382000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
372000
CY2022Q3 fstx Lessee Operating Lease Liability Payments Due After Four Years
LesseeOperatingLeaseLiabilityPaymentsDueAfterFourYears
657000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2839000
fstx Lessee Operating Sublease Term Of Contract
LesseeOperatingSubleaseTermOfContract
P6Y1M6D
CY2022Q3 fstx Future Minimum Sublease Rentals Sales Leaseback Transactions Remainder Of Fiscal Year
FutureMinimumSubleaseRentalsSalesLeasebackTransactionsRemainderOfFiscalYear
116000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions Within One Year
FutureMinimumSubleaseRentalSaleLeasebackTransactionsWithinOneYear
474000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions Within Two Years
FutureMinimumSubleaseRentalSaleLeasebackTransactionsWithinTwoYears
486000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions Within Three Years
FutureMinimumSubleaseRentalSaleLeasebackTransactionsWithinThreeYears
498000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions Within Four Years
FutureMinimumSubleaseRentalSaleLeasebackTransactionsWithinFourYears
511000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions Thereafter
FutureMinimumSubleaseRentalSaleLeasebackTransactionsThereafter
970000
CY2022Q3 fstx Future Minimum Sublease Rental Sale Leaseback Transactions
FutureMinimumSubleaseRentalSaleLeasebackTransactions
3055000
CY2022Q3 us-gaap Contractual Obligation
ContractualObligation
8500000
fstx Number Of Demand Letters Received
NumberOfDemandLettersReceived
8

Files In Submission

Name View Source Status
0000950170-22-024526-index-headers.html Edgar Link pending
0000950170-22-024526-index.html Edgar Link pending
0000950170-22-024526.txt Edgar Link pending
0000950170-22-024526-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fstx-20220930.htm Edgar Link pending
fstx-20220930.xsd Edgar Link pending
fstx-ex31_1.htm Edgar Link pending
fstx-ex31_2.htm Edgar Link pending
fstx-ex32_1.htm Edgar Link pending
fstx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
fstx-20220930_cal.xml Edgar Link unprocessable
fstx-20220930_def.xml Edgar Link unprocessable
fstx-20220930_lab.xml Edgar Link unprocessable
fstx-20220930_pre.xml Edgar Link unprocessable
fstx-20220930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable